Singapore, Jan. 14 -- US based WuXi Advanced Therapies (AT), a leading global Contract Development and Manufacturing Organization (CDMO) offering end-to-end contract services for the advance therapies industry, has announced the expansion of its service capabilities by offering a fully integrated adeno-associated virus (AAV) Vector Suspension Platform to help accelerate the timeline for cell and gene therapy development, manufacturing and release while providing greater predictability.

This service will provide advanced therapy companies worldwide with an integrated platform for AAV vector production that includes: in-stock raw materials with established batch records; regulatory and technical expertise; process and analytical developmen...